Biotech Startups

Wavebreak develops a drug discovery platform targeting amyloid oligomers, toxic protein intermediates implicated in neurodegenerative diseases including Alzheimer's and Parkinson's. The company aims to address previously undruggable molecular pathways underlying neuronal death.

2 investors

WCG advances clinical trial efficiency and outcomes through research services and advisory support. The company serves the medical research and clinical trial industry.

2 investors

Wellthy Therapeutics develops digital therapeutics and clinical decision support tools for pharmaceutical and life science partners to address treatment adherence, patient outcomes, and eligibility challenges in complex clinical conditions and rare diseases. The company builds software-as-a-medical-device (SaMD) solutions, companion therapeutics, and remote patient monitoring platforms with medical-grade compliance.

2 investors

Women-led biotech company engineering high-performance protein-based textile fibers for fashion with sustainable alternatives to synthetic fibers.

2 investors

Winsantor is a clinical-stage biotechnology company developing treatments for peripheral neuropathies, including diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy. The company is currently advancing its lead drug candidate, WST-057, through Phase 2 clinical trials in Canada.

2 investors

Wittgen Bio applies single-cell generative AI to reconstruct cellular-level profiles from bulk RNA or image samples, producing virtual patient profiling for patient stratification. It targets clinical trial teams in oncology, aiming to de-risk trials by identifying responder populations and extracting biomarkers from existing samples.

2 investors

Wobble Genomics operates an RNA sequencing platform that captures full-length RNA transcripts to identify long RNA biomarkers and novel isoforms for precision medicine. It serves pharmaceutical and diagnostics companies, supporting biomarker discovery, patient stratification, diagnostics, and therapeutic development.

2 investors

WonderLab develops research-based probiotic health products for consumer households, spanning gut health, weight management, women's health, oral and sleep microbiome, and children's products. The company operates R&D platforms covering microbiome research, functional ingredient study, and product development in partnership with universities and research institutions, with a stated focus on the Chinese market.

2 investors

Woolsey Pharmaceuticals Pty Ltd (Woolsey AU) is the Australian subsidiary of Woolsey Pharmaceuticals, Inc., leading the company's corporate research and development activities in Australia. It operates in the pharmaceutical and biotech sector.

2 investors

Woven Science backs, incubates, and builds companies in the psychedelic and wellness space, operating across drug development, health technology, and plant-medicine product development and distribution. It also runs El Puente, an initiative focused on access and benefit-sharing between psychedelic companies and indigenous peoples.

2 investors

未知君 (XBiome) develops microbiome-based therapeutics and diagnostics using AI-driven bioengineering, targeting diseases including cancer immunotherapy, inflammatory conditions, and autism through live bacterial therapeutics and fecal microbiota transplantation (FMT). The company operates in China with clinical development, manufacturing, and computational biology capabilities across multiple cities.

2 investors

Xerient is a biopharmaceutical company developing oncology treatments, with expertise in clinical trial design, radiation oncology, and translational cancer research for gastrointestinal malignancies.

2 investors

Xibus Systems develops a pathogen detection system that combines engineered bio-molecules, super fluorescent nano-beads, custom bacterial growth media, and AI analytical software to detect disease-causing bacteria in foods and beverages. The company serves the food and beverage safety industry with faster, more sensitive bacterial detection.

2 investors

Xilis, Inc. was a company that developed micro-organosphere (MOS) technology for laboratory use; the company has closed and its MOS technology is now sold by Uniform Bio as the MOSgen benchtop instrument.

2 investors

Enabling precision medicine through patient-derived micro-organoids.

2 investors

xMD Diagnostics develops laboratory instruments and consumables for molecular diagnostics, aimed at enriching samples for downstream molecular testing. It serves research, biopharmaceutical, and clinical (CLIA) laboratories to help pathologists, oncologists, and other physicians diagnose, monitor, and treat cancer and other genetic diseases.

2 investors

Xpan develops a single universal trocar for minimally invasive surgery (MIS) that accommodates all surgical instruments, aiming to replace traditional trocar access. The device is intended for MIS surgeons and the surgical device market.

2 investors

Xterna develops xeno nucleic acid (XNA) technology to engineer cell-specific binders aimed at treating diseases currently considered untreatable. The company operates in the biotechnology and therapeutics space.

2 investors

XWPharma develops internally discovered small-molecule medicines, focusing on new chemical entities that target time-regulated neurobiology to treat neurological conditions. The company runs its own drug discovery and clinical development programs aimed at high-value therapeutic markets.

2 investors

Yellowbird Diagnostics develops plug-and-play imaging dyes for common medical imaging procedures, designed to reveal disease markers for earlier diagnosis of conditions affecting the brain, heart, and kidneys. The products are aimed at clinicians and patients needing early diagnosis of these diseases.

2 investors

Zentalis is a biopharmaceutical company developing azenosertib and other pipeline assets, seeking strategic partnerships to advance drug development and expand market reach globally.

2 investors

Zeph develops a digital health platform with clinical-grade sensors to help patients manage respiratory conditions like COPD through home-based rehabilitation and evidence-based exercises. The platform serves patients, clinicians, and care teams seeking better respiratory health management.

2 investors

Zeroshot bio builds biology foundation models and AI pipelines that translate zebrafish drug-exposure data, combined with high-throughput single-cell RNA sequencing, into human pre-clinical insights. It generates compound rankings to accelerate hit-to-lead decisions for therapeutics developers.

2 investors

Shanghai Zhenge Biotech is an independent CDMO company providing contract development and manufacturing services for biopharmaceutical clients during clinical development and commercialization phases. The company offers a comprehensive range of services including drug development, cell line construction, process development, analytical methods, raw material production, drug formulation, stability studies, and animal cell culture media development.

2 investors